{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:07:16Z","timestamp":1790874436087,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.cca.2024.117887","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T12:55:36Z","timestamp":1713704136000},"page":"117887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A benefit risk approach in cutoff determination for diagnostic tests"],"prefix":"10.1016","volume":"559","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4998-1121","authenticated-orcid":false,"given":"Jeng","family":"Mah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Magari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen KW","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Winden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2024.117887_b0005","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"10.1016\/j.cca.2024.117887_b0010","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/01621459.2000.10473930","article-title":"Receiver operating characteristic methodology","volume":"95","author":"Pepe","year":"2000","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.cca.2024.117887_b0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/sim.9222","article-title":"Joint Inference about the AUC and youden index for paired biomarkers","volume":"41","author":"Yin","year":"2022","journal-title":"Stat Med."},{"key":"10.1016\/j.cca.2024.117887_b0020","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1161\/CIRCULATIONAHA.105.594929","article-title":"Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models","volume":"115","author":"Zou","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2024.117887_b0025","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cca.2013.02.006","article-title":"Brief critical review: Statistical assessment of biomarker performance","volume":"419","author":"Kampfrath","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2024.117887_b0030","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"10.1016\/j.cca.2024.117887_b0035","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1651-2227.2006.00178.x","article-title":"Understanding diagnostic tests 3: Receiver operating characteristic curves","volume":"96","author":"Akobeng","year":"2007","journal-title":"Acta P\u00e6diatrica."},{"key":"10.1016\/j.cca.2024.117887_b0040","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s40264-020-00984-7","article-title":"Benefit-risk assessment of vaccines. Part I: A systematic review to identify and describe studies about quantitative benefit-risk models applied to vaccines","volume":"43","author":"Arlegui","year":"2020","journal-title":"Drug Saf."},{"issue":"43","key":"10.1016\/j.cca.2024.117887_b0045","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s40264-020-00982-9","article-title":"Benefit-risk assessment of vaccines. Part II: Proposal towards consolidated standards of reporting quantitative benefit-risk models applied to vaccines (BRIVAC)","volume":"2020","author":"Arlegui","year":"2020","journal-title":"Drug Saf."},{"key":"10.1016\/j.cca.2024.117887_b0050","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/cpt.2024","article-title":"Benefit-risk assessment of esketamine nasal spray vs. Placebo in treatment-resistant depression","volume":"109","author":"Katz","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"issue":"36","key":"10.1016\/j.cca.2024.117887_b0055","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/sim.7033","article-title":"Estimands in clinical trials \u2013 broadening the perspective","volume":"2017","author":"Akacha","year":"2017","journal-title":"Statist. Med."},{"key":"10.1016\/j.cca.2024.117887_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106073","article-title":"A new framework to address challenges in quantitative benefit-risk assessment for medical products","volume":"95","author":"Fu","year":"2020","journal-title":"Contemp Clin Trials."},{"key":"10.1016\/j.cca.2024.117887_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2042098620976951","article-title":"Structured benefit-risk evaluation for medicinal products: Review of quantitative benefit-risk assessment findings in the literature","volume":"11","author":"K\u00fcrzinger","year":"2020","journal-title":"Ther Adv Drug Saf."},{"key":"10.1016\/j.cca.2024.117887_b0070","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s43441-020-00230-3","article-title":"Quantitative benefit-risk assessment: State of the practice within industry","volume":"55","author":"Smith","year":"2021","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.cca.2024.117887_b0075","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jval.2016.04.006","article-title":"Patient-focused benefit-risk analysis to inform regulatory decisions: The european union perspective","volume":"19","author":"M\u00fchlbacher","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.cca.2024.117887_b0080","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cpt.871","article-title":"A benefit-risk analysis approach to capture regulatory decision-making: Multiple myeloma","volume":"103","author":"Raju","year":"2020","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.cca.2024.117887_b0085","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s43441-020-00197-1","article-title":"Predicting regulatory product approvals using a proposed quantitative version of FDA\u2019s benefit-risk framework to calculate net-benefit score and benefit-risk ratio","volume":"55","author":"Sun","year":"2021","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.cca.2024.117887_b0090","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/clpt.2010.291","article-title":"Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines","volume":"89","author":"Coplan","year":"2011","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.cca.2024.117887_b0095","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/pds.3676","article-title":"Benefit-risk assessment in a post-market setting: a case study integrating real-life experience into benefit-risk methodology","volume":"23","author":"Hallgreen","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.cca.2024.117887_b0100","doi-asserted-by":"crossref","DOI":"10.1177\/2042098619871180","article-title":"Benefit-risk evaluation: the past, present, and future","volume":"10","author":"Juhaeri","year":"2019","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.cca.2024.117887_b0105","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jval.2016.04.008","article-title":"Patient preferences in regulatory benefit-risk assessments: a US perspective","volume":"19","author":"Johnson","year":"2016","journal-title":"Value Health."},{"key":"10.1016\/j.cca.2024.117887_b0110","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1177\/2168479014565469","article-title":"Benefit-risk evaluation and decision making: some practical insights","volume":"49","author":"Colopy","year":"2015","journal-title":"Thera Innov Reg Sci."},{"key":"10.1016\/j.cca.2024.117887_b0115","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bcp.14425","article-title":"Advancing structured decision-making in drug regulation at the FDA and EMA","volume":"87","author":"Angelis","year":"2021","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.cca.2024.117887_b0120","unstructured":"Benefit-Risk Assessment in Drug Regulatory Decision-Making Draft PDUFA VI Implementation Plan (FY 2018-2022) https:\/\/www.fda.gov\/media\/112570\/download?attachment (accessed 29 December 2023)."},{"key":"10.1016\/j.cca.2024.117887_b0125","unstructured":"Structured Approach to Benefit-Risk Assessment in Drug Regulatory Decision-Making Draft PDUFA V Implementation Plan https:\/\/www.fda.gov\/media\/84831\/download (accessed 29 December 2023)."},{"key":"10.1016\/j.cca.2024.117887_b0130","unstructured":"FDA Guidance for Industry Benefit-Risk Assessment for New Drug and Biological Products."},{"key":"10.1016\/j.cca.2024.117887_b0135","unstructured":"European Medicines Agency: Benefit-Risk Methodology Project, 2012, London. https:\/\/www.ema.europa.eu\/en\/about-us\/what-we-do\/regulatory-science-research\/benefit-risk-methodology (accessed 4 January 2024)."},{"key":"10.1016\/j.cca.2024.117887_b0140","unstructured":"European Medicines Agency: ICH Guideline E2C (R2) on Periodic Benefit-Risk Evaluation Report (PBRER) https:\/\/www.ema.europa.eu\/en\/ich-e2c-r2-periodic-benefit-risk-evaluation-report-scientific-guideline (accessed 4 January 2024)."},{"key":"10.1016\/j.cca.2024.117887_b0145","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1128\/jcm.31.5.1256-1261.1993","article-title":"Determination of the optimal cutoff value for a serological assay: an Example using the johne's absorbed EIA","volume":"31","author":"Ridge","year":"1993","journal-title":"J Clin Microbiology."},{"key":"10.1016\/j.cca.2024.117887_b0150","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/10543406.2016.1226335","article-title":"Comparing diagnostic tests on benefit-risk","volume":"26","author":"Pennello","year":"2016","journal-title":"J. Biopharm. Stat."},{"key":"10.1016\/j.cca.2024.117887_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/aos\/1176344552","article-title":"Another look at the Jackknife","volume":"7","author":"Efron","year":"1979","journal-title":"Ann. Stat."},{"key":"10.1016\/j.cca.2024.117887_b0160","series-title":"Appendix 1, The delta method in applied survival analysis: Regression modeling of time-to-event data","first-page":"355","author":"Hosmer","year":"2008"},{"key":"10.1016\/j.cca.2024.117887_b0165","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijid.2021.07.010","article-title":"Diagnostic accuracy of a SARS-Cov-2 rapid antigen test in real-life clinical settings","volume":"19","author":"Jegerlehner","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.cca.2024.117887_b0170","doi-asserted-by":"crossref","first-page":"20451","DOI":"10.1038\/s41598-021-99712-z","article-title":"Epidemiological and economic impact of COVID-19 in the US","volume":"11","author":"Chen","year":"2021","journal-title":"Sci Rep."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124001281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124001281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:46:53Z","timestamp":1790873213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898124001281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":34,"alternative-id":["S0009898124001281"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2024.117887","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A benefit risk approach in cutoff determination for diagnostic tests","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2024.117887","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117887"}}